Literature DB >> 21464718

Trends in cancer mortality in Mexico, 1981-2007.

Cristina Bosetti1, Teresa Rodríguez, Liliane Chatenoud, Paola Bertuccio, Fabio Levi, Eva Negri, Carlo La Vecchia.   

Abstract

The objective of this study was to provide information on recent trends in cancer mortality in Mexico. We analyzed data provided by the World Health Organization, using joinpoint analysis to detect changes in trends between 1981 and 2007. For most cancers, mortality was upward but started to decline in the late 1980's/early 1990's for both sexes. Overall cancer mortality was 75.53/100 000 men, world standard, and 69.2/100 000 women in 2005-2007. Mortality from uterine cancer declined by approximately 2.5% per year in the 1990s, and by approximately 5% per year in the last decade, but its rates remained exceedingly high (9.7/100 000 in 2005-2007). Other major declines over recent years were those of stomach cancer (approximately 2.5% per year, with rates of 6.6/100 000 in men and 4.9/100 000 in women in 2005-2007) and lung cancer (2-2.5% per year, 11.0/100 000 in men and 4.5/100 000 in women in 2005-2007). Mortality leveled off only since the early 1990s for breast and prostate, and since the late 1990s for colorectal cancer. Death rates from cancer in Mexico remained low on a worldwide scale and showed favorable trends over more recent calendar years. Mortality from (cervix) uterine cancer still represents a major public health priority in this country.

Entities:  

Mesh:

Year:  2011        PMID: 21464718     DOI: 10.1097/CEJ.0b013e32834653c9

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  9 in total

Review 1.  Epidemiology of renal cancer in developing countries: Review of the literature.

Authors:  Mauricio Medina-Rico; Hugo López Ramos; Manuel Lobo; Jorge Romo; Juan Guillermo Prada
Journal:  Can Urol Assoc J       Date:  2017-12-22       Impact factor: 1.862

2.  Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer.

Authors:  Gabriela Torres-Mejía; Robert Royer; Marcia Llacuachaqui; Mohammad R Akbari; Anna R Giuliano; Louis Martínez-Matsushita; Angélica Angeles-Llerenas; Carolina Ortega-Olvera; Elad Ziv; Eduardo Lazcano-Ponce; Catherine M Phelan; Steven A Narod
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-04       Impact factor: 4.254

3.  Cervical Cancer in Young Women: Do They Have a Worse Prognosis? A Retrospective Cohort Analysis in a Population of Mexico.

Authors:  David Isla-Ortiz; Elizabeth Palomares-Castillo; José Emilio Mille-Loera; Nora Ramírez-Calderón; Alejandro Mohar-Betancourt; Abelardo A Meneses-García; Nancy Reynoso-Noverón
Journal:  Oncologist       Date:  2020-05-28

4.  Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico.

Authors:  Oscar Arrieta; Roger Humberto Quintana-Carrillo; Gabriel Ahumada-Curiel; Jose Francisco Corona-Cruz; Elma Correa-Acevedo; Juan Zinser-Sierra; Dolores de la Mata-Moya; Alejandro Mohar-Betancourt; Vicente Morales-Oyarvide; Luz Myriam Reynales-Shigematsu
Journal:  Tob Induc Dis       Date:  2015-02-04       Impact factor: 2.600

5.  Diet, obesity and colorectal carcinoma risk: results from a national cancer registry-based middle-eastern study.

Authors:  Nourah Alsheridah; Saeed Akhtar
Journal:  BMC Cancer       Date:  2018-12-07       Impact factor: 4.430

6.  Analysis of population-based colorectal cancer screening in Guangzhou, 2011-2015.

Authors:  Feng Zhiqiang; Cao Jie; Nie Yuqiang; Gong Chenghua; Wang Hong; Sun Zheng; Li Wanglin; Zhou Yongjian; Dai Liping; Zeng Lizhong; Zhao DeJian
Journal:  Cancer Med       Date:  2019-03-29       Impact factor: 4.452

7.  Biomarkers in prostate cancer epidemiology.

Authors:  Mukesh Verma; Payal Patel; Mudit Verma
Journal:  Cancers (Basel)       Date:  2011-09-30       Impact factor: 6.639

8.  Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia.

Authors:  Julián Esteban Londoño Hernández; Marcia Llacuachaqui; Gonzalo Vásquez Palacio; Juan David Figueroa; Jorge Madrid; Mauricio Lema; Robert Royer; Song Li; Garrett Larson; Jeffrey N Weitzel; Steven A Narod
Journal:  Hered Cancer Clin Pract       Date:  2014-04-17       Impact factor: 2.857

9.  ECOG is as independent predictor of the response to chemotherapy, overall survival and progression-free survival in carcinoma of unknown primary site.

Authors:  Rocío Grajales-Álvarez; Ana Martin-Aguilar; Juan A Silva; Jaime G De La Garza-Salazar; Erika Ruiz-García; César López-Camarillo; Laurence A Marchat; Horacio Astudillo-De La Vega
Journal:  Mol Clin Oncol       Date:  2017-04-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.